PROF Profound Medical Corp.

Global debt costs are climbing, with interest bills now larger than many governments spend on AI itself. That squeeze on public budgets is pushing attention toward private companies building real AI tools that healthcare providers can pay for and use today. Canadian AI in medicine sits right in that conversation. This article breaks down three stocks from our AI healthcare screen that show how this theme is playing out in practice. The stocks covered below are just a sample from this theme,...

Canada’s Ivey PMI recently hit a multi year high, hinting that businesses are spending again on tools that cut costs and raise productivity. That backdrop puts artificial intelligence in healthcare on many watchlists. AI can help Canadian hospitals and drug developers do more with limited budgets. This article walks through three AI focused healthcare stocks from our screener that could interest investors watching this shift. The stocks below are just a sample from this theme, and the full...

Record orders and expanding payer coverage mark commercial inflection.

Moby summary of Profound Medical Corp.'s Q2 2026 earnings call

Profound Medical (NASDAQ:PROF) reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June. Corporate Controller Matthew Sobczyk

Despite a $3.1 million shipment timing issue, Profound Medical Corp (PROF) posts strong commercial momentum with a record July order month and expanding payer coverage.

Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.